Technical Analysis for PGNX - Progenics Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 4.6 4.07% 0.18
PGNX closed up 4.07 percent on Monday, March 18, 2019, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical PGNX trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Support Bullish 0.00%
Mar 18 Crossed Above 50 DMA Bullish 0.00%
Mar 15 50 DMA Resistance Bearish 4.07%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.07%
Mar 15 20 DMA Support Bullish 4.07%
Mar 15 MACD Bullish Signal Line Cross Bullish 4.07%
Mar 15 Doji - Bearish? Reversal 4.07%
Mar 15 Earnings Movers Other 4.07%
Mar 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.07%
Mar 14 Crossed Above 20 DMA Bullish 4.07%

Older signals for PGNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
Medicine Chemistry Biotechnology Cancer Pain Imaging Solid Tumors Oncology Cancers Prostate Cancer Morphinans Cyclopropanes Neuroblastoma Phenols Adc Constipation Salix Pharmaceuticals
Is PGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.42
52 Week Low 3.62
Average Volume 1,135,029
200-Day Moving Average 6.134
50-Day Moving Average 4.5432
20-Day Moving Average 4.3735
10-Day Moving Average 4.241
Average True Range 0.2236
ADX 16.28
+DI 22.8785
-DI 15.4364
Chandelier Exit (Long, 3 ATRs ) 4.3291
Chandelier Exit (Short, 3 ATRs ) 4.6308
Upper Bollinger Band 4.7965
Lower Bollinger Band 3.9505
Percent B (%b) 0.77
BandWidth 19.343775
MACD Line -0.0536
MACD Signal Line -0.0878
MACD Histogram 0.0342
Fundamentals Value
Market Cap 323.24 Million
Num Shares 70.3 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -76.67
Price-to-Sales 6.47
Price-to-Book 5.52
PEG Ratio -0.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.02
Resistance 3 (R3) 4.98 4.81 4.95
Resistance 2 (R2) 4.81 4.70 4.83 4.93
Resistance 1 (R1) 4.70 4.63 4.76 4.74 4.90
Pivot Point 4.53 4.53 4.55 4.55 4.53
Support 1 (S1) 4.42 4.42 4.48 4.46 4.30
Support 2 (S2) 4.25 4.35 4.27 4.27
Support 3 (S3) 4.14 4.25 4.25
Support 4 (S4) 4.18